Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2023 Jun;58(6):1719-1727.
doi: 10.1002/ppul.26386. Epub 2023 Mar 17.

Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial

Meghan R Roddy  1 , Austin R Sellers  2 , Kristina K Darville  3 , Beatriz Teppa-Sanchez  3 , Scott D McKinley  4 , Meghan Martin  5 , Neil A Goldenberg  2   6   7 , Thomas A Nakagawa  8 , Anthony A Sochet  2   3   9
Affiliations
Controlled Clinical Trial

Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial

Meghan R Roddy et al. Pediatr Pulmonol. 2023 Jun.

Abstract

Background: Evidence for the use of dexamethasone for pediatric critical asthma is limited. We sought to compare the clinical efficacy and safety of dexamethasone versus methylprednisolone among children hospitalized in the pediatric intensive care unit (PICU) for critical asthma.

Methods: A prospective, single center, open-label, two-arm, parallel-group, nonrandomized trial among children ages 5-17 years hospitalized within the PICU from April 2019 to December 2021 for critical asthma consented to receive methylprednisolone (standard care) or dexamethasone (intervention) at a 2:1 allocation ratio, respectively. The intervention arm received intravenous dexamethasone 0.25 mg/kg/dose (max: 15 mg/dose) every 6 h for 48 h and the standard care arm intravenous methylprednisolone 1 mg/kg/dose every 6 h (max dose: 60 mg/dose) for 5 days. Study endpoints were clinical efficacy (i.e., length of stay [LOS], continuous albuterol duration, and a composite of adjunctive asthma interventions) and safety (i.e., corticosteroid-related adverse events).

Results: Ninety-two participants were analyzed of whom 31 were allocated to the intervention arm and 61 the standard care arm. No differences in demographics, clinical characteristics, or acute/chronic asthma severity indices were observed. Regarding efficacy and safety endpoints, no differences in hospital LOS, continuous albuterol duration, adjunctive asthma intervention rates, or corticosteroid-related adverse events were noted. Compared to the intervention arm, participants in the standard care arm more frequently were prescribed corticosteroids at discharge (72% vs. 13%, p < 0.001).

Conclusions: Among children hospitalized for critical asthma, dexamethasone appears safe and warrants further investigation to fully assess clinical efficacy and potential advantages over commonly applied agents such as methylprednisolone.

Keywords: corticosteroids; glucocorticoids; pediatric critical care medicine; pediatric intensive care unit; status asthmaticus.

PubMed Disclaimer

References

REFERENCES

    1. United States Centers for Disease Control and Prevention. Most recent national asthma data; [updated 2021 Mar 30; cited 2022 May 1]. 2017-2019 National Health Interview Survey (NHIS). https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
    1. Shanley LA, Lin H, Flores G. Factors associated with length of stay for pediatric asthma hospitalizations. J Asthma. 2015;52:471-477.
    1. Fassl BA, Nkoy FL, Stone BL, et al. The joint commission children's asthma care quality measures and asthma readmissions. Pediatrics. 2012;130:482-491.
    1. Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. Pediatrics. 2009;123:S131-S145.
    1. Schivo M, Phan C, Louie S, Harper RW. Critical asthma syndrome in the ICU. Clin Rev Allergy Immunol. 2015;48:31-44.

Publication types